Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

Linda Stein Gold, MD

This episode, titled ‘Choosing Between Oral and Injectable PsO Therapy,’ features panelists discussing how route of administration influences systemic treatment decisions in plaque psoriasis. Historically, patients who prioritized efficacy were often steered toward biologic therapy even when they initially preferred an oral medication. The panel explains that this conversation is changing as newer oral therapies demonstrate greater efficacy and provide clinicians with more competitive alternatives.

Choosing Between Oral and Injectable PsO Therapy

Faculty discuss why patient preference cannot be reduced to simply choosing a pill over a needle. Injection frequency, ease of administration, safety, travel, refrigeration, and comfort with self-injection all influence how patients perceive biologic therapy. Some patients may be comfortable with an injection given only a few times per year, while others strongly prefer the familiarity and flexibility of a daily oral medication.

The experts also describe how newer oral options may be especially reassuring for patients taking their first step into systemic therapy. An oral medication may feel less intimidating and offers the perceived flexibility of stopping therapy without the prolonged exposure associated with some injectable agents. At the same time, widespread use of injectable therapies in other areas of medicine may be making some patients more comfortable with injections.

In the next episode, ‘Understanding the Pathophysiology of PsO,’ panelists will review the pathophysiology of psoriasis and explain how PDE4, TYK2, and IL-23–targeted oral therapies act within key inflammatory pathways.

Videos

Route of administration is becoming a more balanced decision as newer oral therapies narrow historical differences in treatment efficacy.

In ‘Overcoming Delays in Systemic Treatment Escalation for PsO,’ our panel explores why some patients with plaque psoriasis remain on topical therapy despite persistent disease burden and potential candidacy for systemic treatment. The discussion begins with data showing that patients with relatively low body surface area may still perceive their psoriasis as moderate and that many continue to cycle through multiple topical therapies without escalating treatment.

Overcoming Delays in Systemic Treatment Escalation for PsO

The faculty identify several reasons for delayed escalation, including clinician comfort with systemic therapy, longstanding reliance on topical treatment in dermatology, and concerns about safety with newer medications. Dr. Stein Gold describes how conversations can change when psoriasis is framed not simply as a skin condition but as a systemic inflammatory disease, particularly when patients have substantial disease burden or possible psoriatic arthritis.

The panel also stresses the importance of clinician confidence and education. As systemic therapies have become more targeted and extensively studied, the faculty argue that providers should understand both their benefits and risks well enough to discuss them clearly with patients. Modern psoriasis care increasingly requires determining when topical treatment is no longer sufficient and when a systemic approach is more appropriate.

Our next episode, ‘Choosing Between Oral and Injectable PsO Therapy,’ examines how route of administration influences treatment decisions and how newer oral therapies may provide additional choices for patients considering systemic treatment.

Recognizing psoriasis as a systemic disease may help clinicians move appropriate patients beyond repeated topical treatment.

As therapies improve, complete clearance and meaningful quality-of-life gains are increasingly shaping expectations for psoriasis care.

Redefining Treatment Goals and Patient Expectations in PsO

In this episode, ‘Redefining Treatment Goals and Patient Expectations in PsO,’ the expert dermatology panel explores how treatment expectations in plaque psoriasis have changed alongside advances in therapy. Faculty reflect on the progression of clinical trial benchmarks from PASI 50 to PASI 75, PASI 90, and increasingly PASI 100 as newer therapies have made deeper levels of skin clearance achievable.

The panel emphasizes that complete clearance is more than a clinical trial endpoint. Even limited residual psoriasis may remain visible, symptomatic, or disruptive to daily life, and patients may continue to experience meaningful quality-of-life impairment despite low overall disease burden. The experts discuss why complete clearance has therefore become an increasingly relevant treatment goal and how these higher expectations have influenced both clinical practice and patient conversations.

Beyond skin clearance, the discussion highlights symptoms such as itch, burning, and pain, as well as safety, tolerability, comorbidities, cost, and access. The faculty note that treatment success must account for the broader experience of living with psoriasis rather than relying solely on body surface area or a physician-assessed skin score. As newer therapies continue to improve disease control, the panel considers how goals that once seemed aspirational are becoming increasingly realistic.

The next episode in this series, ‘Overcoming Delays in Systemic Treatment Escalation for PsO,’ features the panelists examining why patients may remain on topical therapy despite persistent disease and why timely escalation to systemic treatment can matter.

Advances across topical, biologic, and oral therapies are expanding the possibilities for individualized systemic psoriasis care.

Evolving Treatment Options in PsO

Welcome back to another HCPLive Peer Exchange series. In this episode titled, ‘Evolving Treatment Options in PsO,’ the panel of experts reviews how the plaque psoriasis treatment landscape has evolved and where topical, biologic, and oral systemic therapies fit within current care. The faculty describe the substantial gains achieved with biologic therapies, which have raised expectations for achieving clear or almost-clear skin in patients with moderate-to-severe disease. They also discuss advances in nonsteroidal topical therapies and their continued role for patients with limited disease as well as adjunctive use alongside systemic treatment.

The conversation then turns to a historically important gap in the oral treatment space. The panel explains that earlier oral options did not always provide the combination of efficacy, tolerability, and safety clinicians had come to expect from newer biologic therapies. With the emergence of newer targeted oral agents, however, clinicians now have additional systemic options for patients who may prefer a pill or who are taking the first step beyond topical treatment. Faculty discuss how they integrate these different approaches in practice and emphasize that treatment choice depends on disease burden, high-impact involvement, prior topical response, and individual patient needs.

In the next episode, ‘Redefining Treatment Goals and Patient Expectations in PsO,’ panelists will continue their discussion on plaque psoriasis and highlight how expectations have progressed from partial improvement toward complete clearance and outcomes that matter most to patients.

Linda Stein Gold, MD

Articles